News Image

Erasca Reports First Quarter 2024 Business Updates and Financial Results

Provided By GlobeNewswire

Last update: May 8, 2024

Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma

Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors

Read more at globenewswire.com

ERASCA INC

NASDAQ:ERAS (7/31/2025, 8:20:52 PM)

After market: 1.41 -0.01 (-0.35%)

1.415

-0.13 (-8.71%)



Find more stocks in the Stock Screener

Follow ChartMill for more